Prevalence of Chagas Disease in Immigrant Patients With Conduction Abnormalities on Electrocardiogram

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

327 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-01-31

Study Completion Date

2010-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chagas disease is endemic to the Americas, infecting between 16-18 million individuals. In immigrant populations in the United States from endemic areas, it is estimated up to 4.9% may be asymptomatic carriers of Trypanosoma cruzi, the organism which causes Chagas disease. Between 10-20% of these patients progress to development of end-stage cardiomyopathy with a high associated morbidity. Following acute disease, patients enter into an indeterminate phase which can last 10-20 years. The earliest sign of cardiac involvement usually is electrocardiogram abnormalities. The most common abnormality is right bundle branch block (RBBB), followed by left anterior fascicular block (LAFB), and left bundle branch block (LBBB). Recent studies have shown that treatment of patients at this stage with antiparasitics may delay the progression of overt cardiomyopathy.

At the University of California, Los Angeles, there is a large population of immigrant patients from countries endemic to Chagas disease. The researchers propose that screening patients with conduction abnormalities on electrocardiogram may be a potentially useful method to identify patients with early cardiac manifestations of Chagas disease. The researchers hope to enroll approximately 300 individuals with RBBB, LAFB or LBBB on electrocardiogram to determine the incidence of Chagas disease in this patient population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

New Tools for the Diagnosis, Prognosis and Treatment Follow-up in Chagas Disease

NCT01755377

Chagas Disease

COMPLETED

New Therapies and Biomarkers for Chagas Infection

NCT03981523

Trypanosoma Cruzi Infection Chagas Disease

COMPLETED PHASE2

Chagas Disease Diagnostic - Inconclusive Serology

NCT00511589

Parasitemia Protozoan Infections

COMPLETED NA

Congenital Chagas Disease: Long Term Follow up of Treated Children. Preliminary Report or Cardiological Evaluation in Chagas Disease Treated Children

NCT04090489

Chagas Disease Chagas Cardiomyopathy

COMPLETED

University-Based Chagas Testing in Salta Province, Argentina

NCT07033325

Chagas Disease Trypanosoma Cruzi Infection Chronic Chagas Disease

ENROLLING_BY_INVITATION

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chagas Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

serological testing

In Latin American immigrants diagnosed with nonischemic cardiomyopathy in Los Angeles, serological testing for Trypanosoma cruzi was performed at enrollment.

Trypanosoma cruzi serology

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Trypanosoma cruzi serology

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* One of the following EKG abnormalities:

* Complete or incomplete right bundle branch block (RBBB)
* Left anterior fascicular block (LAFB)
* Left bundle branch block (LBBB)
* Residence at any point in past in an endemic area (any country in Central or South America or Mexico) for at least 12 months.
* Age \>18 and \<60.